MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Pfizer (PFE) announced results from the Phase 3 TALAPRO-2 study of TALZENNA, an oral poly ADP-ribose polymerase inhibitor, in combination with ...
Bullish option flow detected in Pfizer (PFE) with 70,941 calls trading, 1.3x expected, and implied vol increasing over 1 point to 23.18%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback